Non-Narcotic Analgesics Allergy Labels Linked to Adverse Maternal and Fetal Outcomes

A seemingly innocuous listing on a patient’s medical chart – an allergy to non-narcotic analgesics – may be linked to a range of adverse outcomes for both mother and baby, according to research presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The study, a retrospective analysis of births in California between 2016 and 2021, suggests a need for careful evaluation of patients with this allergy label.

Unexpected Connections

Researchers, led by Chang Su, MD, found a connection between a non-narcotic analgesics allergy label (NNAAL) and increased risks during pregnancy and childbirth. “There is a paucity of information regarding the effect of a non-narcotic analgesics allergy label on maternal and fetal outcomes,” Dr. Su stated. The study examined 2,244,210 singleton livebirths, identifying 10,460 cases where mothers had an NNAAL.

Specific Risks Identified

The analysis revealed a significantly higher rate of eclampsia – a dangerous complication of pregnancy characterized by seizures – in mothers with NNAALs (aRR 1.5, 95% CI [1.06, 2.12]). Increased risks were also observed for preterm birth (aRR 1.21, 95% CI [1.14, 1.28]), and admission to the Neonatal Intensive Care Unit (NICU) (aRR 1.17, 95% CI [1.10, 1.25]).

Did You Know? The study analyzed data from all births in California between 2016 and 2021, encompassing over 2.2 million singleton livebirths.

Further findings indicated a higher incidence of infants experiencing neonatal withdrawal syndrome (aRR 1.51, 95% CI [1.24, 1.84]) and longer hospital stays for newborns. Notably, mothers with NNAALs were also more likely to be over 34 years old.

Potential for Improvement

Dr. Su and colleagues suggest that approximately 80% of patients with a history of non-narcotics analgesics allergy could potentially be “delabeled” through further evaluation. This delabeling, they believe, could lead to improved outcomes for both mothers and infants.

Expert Insight: Identifying and addressing potentially inaccurate allergy labels could represent a proactive step toward optimizing maternal and fetal health, highlighting the importance of thorough patient history review and allergy assessment.

The research underscores the need for healthcare providers to proactively evaluate patients with NNAALs, potentially improving perinatal outcomes.

Frequently Asked Questions

What is a non-narcotic analgesics allergy label?

A non-narcotic analgesics allergy label (NNAAL) indicates a reported allergy to pain relievers that are not opioids.

What were the key findings of this study?

The study found that mothers with NNAALs had increased rates of eclampsia, preterm birth, NICU admission, and infants with neonatal withdrawal syndrome.

What is the potential next step based on this research?

Researchers suggest evaluating women of childbearing age with a history of non-narcotics analgesics allergy to potentially remove the allergy label, which could improve perinatal outcomes.

Given these findings, how might a more thorough review of patient allergy histories impact prenatal care?